ICAAC Highlights In Brief: The Liposome Company's ABLC
Executive Summary
The Liposome Company's ABLC: In a 231-patient Phase III study comparing ABLC (amphotericin B lipid complex) to conventional amphotericin B in patients with invasive candidiasis, nephrotoxicity is "significantly greater in patients receiving amphotericin B," investigators reported at ICAAC Sept. 18. "Baseline serum creatinine doubled in only 28% of ABLC patients compared to 47% of amphotericin B patients," Princeton, New Jersey-based TLC reports. "The median number of days before serum creatinine doubled was significantly (p=.028) shorter for the amphotericin B patients (19 days for amphotericin B versus 82 days for ABLC)." Response rates and mycological eradication rates for the two formulations were similar: 65% v. 61% and 88% v. 87% for ABLC and amphotericin B, respectively. TLC filed an NDA for ABLC for the treatment of aspergillosis in May...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth